U.S. Markets closed
  • S&P Futures

    4,034.50
    -1.25 (-0.03%)
     
  • Dow Futures

    32,749.00
    -25.00 (-0.08%)
     
  • Nasdaq Futures

    12,871.00
    +3.75 (+0.03%)
     
  • Russell 2000 Futures

    1,793.40
    +0.10 (+0.01%)
     
  • Crude Oil

    69.50
    +0.17 (+0.25%)
     
  • Gold

    1,947.90
    +6.80 (+0.35%)
     
  • Silver

    22.56
    +0.13 (+0.58%)
     
  • EUR/USD

    1.0774
    +0.0001 (+0.0108%)
     
  • 10-Yr Bond

    3.6060
    +0.1250 (+3.59%)
     
  • Vix

    21.38
    -2.77 (-11.47%)
     
  • GBP/USD

    1.2213
    -0.0006 (-0.0476%)
     
  • USD/JPY

    132.5090
    +0.0490 (+0.0370%)
     
  • BTC-USD

    28,048.73
    +156.92 (+0.56%)
     
  • CMC Crypto 200

    612.06
    +7.02 (+1.16%)
     
  • FTSE 100

    7,536.22
    +132.37 (+1.79%)
     
  • Nikkei 225

    27,326.52
    +380.85 (+1.41%)
     

Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication

  • Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629.

  • Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure.

  • ADX-629 and placebo were well tolerated, and no safety concerns were noted.

  • Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder.

  • In addition to the statistical superiority of ADX-629 over the placebo in Romberg test balance time, flushing, and acetaldehyde, total cholesterol, and LDL levels were statistically lower following ADX-629 treatment than following placebo treatment.

  • Aldeyra plans to initiate a Phase 2 trial of ADX-629 in moderate alcoholic hepatitis in 2023. Results from a Phase 2 trial of ADX-629 in chronic cough are expected in 1H of 2023, and results from Phase 2 clinical trials of ADX-629 in minimal change disease and Sjögren-Larsson Syndrome are expected in 2023.

  • Price Action: ALDX shares are up 0.96% at $6.28 on the last check Tuesday.

  • Photo Via Company

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.